Functional Inhibitor Compounds Inhibit Herpes Simplex Virus Proliferation

Dec 23, 2021

Researchers discuss the challenges in developing specific antiviral drugs due to limited molecular targets in viruses. They explore the use of small compounds to inhibit herpes simplex virus proliferation. Collaborative research focuses on inhibitor compounds for various viruses, including Zika and cytomegalovirus. The podcast outlines the development of wide-range antiviral drugs and drug development plans. Researchers also explore inhibiting virus translation mechanisms for developing effective antiviral drugs.

Ask episode

Chapters

Transcript

Episode notes

Introduction

00:00 • 3min

Collaborative Research on Inhibitor Compounds Against Various Viruses

02:39 • 3min

Developing Wide-Range Antiviral Drugs and Drug Development Plans

05:36 • 2min

Research on Broad-Spectrum Antiviral Drugs Targeting Virus Translation Mechanism

08:03 • 3min

Oncotarget published "Host targeted antiviral (HTA): functional inhibitor compounds of scaffold protein RACK1 inhibit herpes simplex virus proliferation" which reported that due to the small number of molecular targets in viruses and the rapid evolution of viral genes, it is very challenging to develop specific antiviral drugs. In addition, HIV-1 and Herpes Simplex virus are known to use IRES as well. By utilizing the crystal structure of the RACK1A protein from the model plant Arabidopsis and using a structure based drug design method, dozens of small compounds were identified that could potentially bind to the experimentally determined functional site of the RACK1A protein. Dr. Sivanesan Dakshanamurthy from The Georgetown University Medical Center, Dr. Qiyi Tang from The Howard University College of Medicine and Dr. Hemayet Ullah from Howard University said, "With the small number of molecular targets in viruses and the rapid evolution of viral genes, it is very challenging to develop specific antiviral drugs." Full press release - https://www.oncotarget.com/news/pr/functional-inhibitor-compounds-inhibit-herpes-simplex-virus-proliferation/ DOI - https://doi.org/10.18632/oncotarget.26907 Full text - https://www.oncotarget.com/article/26907/text/ Correspondence to - Sivanesan Dakshanamurthy - sd233@georgetown.edu, Qiyi Tang - qiyi.tang@howard.edu, and Hemayet Ullah - hullah@howard.edu Keywords - host targeted antiviral (HTA), herpes simplex virus (HSV), receptor for activated C kinase 1 (RACK1), RACK1 inhibitor, internal ribosomal entry site (IRES) About Oncotarget Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957x105